By Joseph Harvey
March 7, 2017
UK firm Dechra Pharmaceuticals has secured exclusive North American rights to Kane Biotech's StrixNB and DispersinB products.
The deal furthers Dechra's North American companion animal portfolio, specifically in the areas of oral care and dermatology. The company's growing pet product revenues were highlighted in its most recent financial update.
Through the 10-year exclusive license and distribution agreement, Kane will receive an upfront payment of an undisclosed amount. It will also be entitled to a series of potential payments linked to commercial milestones. These additional payments will add up to a maximum of $2 million.
Additionally, Kane will receive an ongoing royalty on net sales of the products in North America. These royalties are subject to certain minimum annual payments.
Winnipeg, Manitoba-based Kane specializes in technologies designed to prevent and remove microbial biofilms. When bacteria are contained in a biofilm, they become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This contributes to numerous animal health problems such as wound care infections, recurrent urinary tract infections, tooth decay and food-borne bacterial infections.
Kane's StrixNB line of products – water additives, an oral spray and a toothpaste – are designed to fight plaque and tartar in dogs and cats. The products were first commercialized in 2014 and are available exclusively in veterinary clinics. Kane said StrixNB tackles dental-associated bacteria by breaking through dental biofilm, leaving bacteria exposed for eradication.
According to Kane, the pet oral care market in the US in 2015 was estimated to be worth $775m and growing at 33% annually.
DispersinB is a dermatological formulation to protect the coat and skin of dogs and horses against atopic dermatitis. The company said DispersinB is effective on methicillin-resistant Staphylococcus pseudintermediusand Malassezia pachydermatis growth and biofilm formation.
Mark Ahrens-Townsend, Kane's president and chief executive, said: "Dechra represents an ideal commercial partner in the specialty veterinarian market for Kane Biotech's StrixNB and DispersinB oral care and dermatology products given its existing commercial footprint, sales force, and synergies with its current product portfolio.
"This license agreement represents an important validation of Kane Biotech's research and development and intellectual property programs, and the market value of our products and technologies by a leading veterinary pharmaceutical company." Reprinted with permission of Animal Pharm News